Medicaid coverage practices for approved gene and cell therapies: Existing barriers and proposed policy solutions.

Publication Year: 2023

DOI:
10.1016/j.omtm.2023.05.015

PMCID:
PMC10242491

PMID:
37287748

Journal Information

Full Title: Mol Ther Methods Clin Dev

Abbreviation: Mol Ther Methods Clin Dev

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Medicine, Research & Experimental

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of interests J.W. is an Independent Director on the Board of Atsena Therapeutics, Inc., and sits on the Board of Directors at ASGCT. R.R. has consulting agreements with and receives honoraria from Pfizer Inc., sits on ASGCT’s Board of Directors, receives research funding from Tessa Therapeutics, and receives honoraria from Kite-Gilead Sciences. The content of this article represents the authors’ opinions and may not necessarily represent the views of their employers."

Evidence found in paper:

"ASGCT; Ultragenyx Pharmaceuticals; ASGCT"

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025